Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.

E. Huijssoon; S. Albani; A.B.J. Prakken; F. van Wijk

Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.

Translated title of the contribution: Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.

E. Huijssoon
, S. Albani
, A.B.J. Prakken
, F. van Wijk

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Mucosal administration of an antigen eliciting bystander suppression at the site of inflammation results in effective antigen-specific immunotherapy for autoimmune diseases. Heat shock proteins are bystander antigens that are effective in peptide-specific immunotherapy in both experimental and human autoimmune disease. The efficacy of preventive peptide immunotherapy is increased by enhancing peptide-specific immune responses with proinflammatory agents. Combining peptide-specific immunotherapy with general suppression of inflammation may improve its therapeutic effect.

Translated title of the contribution	Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.
Original language	Undefined/Unknown
Pages (from-to)	20-29
Number of pages	10
Journal	Clinical and Experimental Immunology
Volume	171
Issue number	1
Publication status	Published - 2013

Access to Document

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2012.04627.x/abstract

Cite this

@article{2caa61a071f544699aa9fa8187c9f8ab,

title = "Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.",

abstract = "Mucosal administration of an antigen eliciting bystander suppression at the site of inflammation results in effective antigen-specific immunotherapy for autoimmune diseases. Heat shock proteins are bystander antigens that are effective in peptide-specific immunotherapy in both experimental and human autoimmune disease. The efficacy of preventive peptide immunotherapy is increased by enhancing peptide-specific immune responses with proinflammatory agents. Combining peptide-specific immunotherapy with general suppression of inflammation may improve its therapeutic effect.",

author = "E. Huijssoon and S. Albani and A.B.J. Prakken and \{van Wijk\}, F.",

year = "2013",

language = "Undefined/Unknown",

volume = "171",

pages = "20--29",

journal = "Clinical and Experimental Immunology",

issn = "0009-9104",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.

AU - Huijssoon, E.

AU - Albani, S.

AU - Prakken, A.B.J.

AU - van Wijk, F.

PY - 2013

Y1 - 2013

N2 - Mucosal administration of an antigen eliciting bystander suppression at the site of inflammation results in effective antigen-specific immunotherapy for autoimmune diseases. Heat shock proteins are bystander antigens that are effective in peptide-specific immunotherapy in both experimental and human autoimmune disease. The efficacy of preventive peptide immunotherapy is increased by enhancing peptide-specific immune responses with proinflammatory agents. Combining peptide-specific immunotherapy with general suppression of inflammation may improve its therapeutic effect.

AB - Mucosal administration of an antigen eliciting bystander suppression at the site of inflammation results in effective antigen-specific immunotherapy for autoimmune diseases. Heat shock proteins are bystander antigens that are effective in peptide-specific immunotherapy in both experimental and human autoimmune disease. The efficacy of preventive peptide immunotherapy is increased by enhancing peptide-specific immune responses with proinflammatory agents. Combining peptide-specific immunotherapy with general suppression of inflammation may improve its therapeutic effect.

M3 - Article

SN - 0009-9104

VL - 171

SP - 20

EP - 29

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

IS - 1

ER -

Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.

Abstract

Access to Document

Fingerprint

Cite this